Search Results 1721-1730 of 19438 for hemoglobin

1. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

   hemoglobin ≥ 9 g/dL (may have been transfused);; alanine aminotransferase (ALT, SGPT) ≤ 3.5 x upper limit of normal (ULN);; aspartate aminotransferase (AST ...

2. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor - Mayo Clinic

   Hemoglobin ≥ 9 g/dL;; Absolute neutrophil count ≥ 1.5 × 109/L;; Platelet count ≥ 100 × 109/L;; ALT and AST ≤ 2.5 × upper limit of normal (ULN), with the ...

3. Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies - Mayo Clinic

   Hemoglobin ≥9.0 g/dL; ANC ≥1.5 x 109/L; Platelet count ≥75 x109/L. Note: For Expansion Cohort 13 (hepatocellular cancer), the platelet count requirement is ...

4. A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients - Mayo Clinic

   Hemoglobin ≥ 11 g/dL;; Platelet count ≥ 100,000 cells/mm^3;; Absolute neutrophil count ≥ 1500 cells/mm^3;; Calculated creatinine clearance ≥ 30 mL/min ...

5. A Study Evaluating Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma - Mayo Clinic

   Hemoglobin (Hgb) >= 8.0 g/dL within 14 days prior to registration. (Note: the use of transfusion of other intervention to achieve a Hgb >= 8.0 g/dL is ...

6. A Study to Evaluate Combination Therapy to Treat Newly-diagnosed Diffuse Anaplastic Wilms Tumors and Relapsed Favorable Histology Wilms Tumors A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dL (may receive red blood cell [RBC] transfusions) (performed within 7 days prior to enrollment). Patients with high-risk or very high ...

7. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Hemoglobin* ≥ 9g/dL. Renal: eGFR (CKD-EPI calculation) ≥ 30 mL/min/1.73m^2. Hepatic: Serum total bilirubin ≤ 1.5 x ULN; or; Direct bilirubin ≤ ULN for ...

8. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma - Mayo Clinic

   * Hemoglobin \>= 9.0 g/dL (obtained =\< 15 days prior to registration) (without transfusion or erythropoietin \[EPO\] dependency =\< 7 days prior to assessment)

9. Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy with Adjuvant PCV Chemotherapy in Patients with Anaplastic Glioma or Low Grade Glioma - Mayo Clinic

   - Hemoglobin (Hgb) > 9.0 g/dL obtained =< 21 days prior to registration - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) obtained =< 21 ...

10. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...